Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy
- Autores
- Reiter, Russel; De Almeida Chuffa, Luiz; Simão, Vinícius; Martín Giménez, Virna Margarita; de Las Heras, Natalia; Spandidos, Demetrios; Manucha, Walter Ariel Fernando
- Año de publicación
- 2024
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Melatonin and vitamin D (VitD) hold significant promise in cancer prevention and treatment due to their shared anti-inflammatory, immune-boosting, and anti-cancer properties. Deficiencies in both agents can arise from modern lifestyles, with low sunlight exposure impacting VitD and excessive artificial light at night suppressing melatonin. Several studies highlight the potential of combining VitD and melatonin supplementation against various cancer types. Research on lip, oral, and pharynx cancers suggests this combination could address antioxidant imbalances linked to the disease. Similarly, promising results from breast, head and neck, brain, and osteosarcoma studies indicate potential for tumor growth inhibition and improved survival and quality of life. Beyond tumor control, this combination has shown significant benefits in lung cancer patients by improving survival, alleviating respiratory symptoms, and enhancing patient’s quality of life. The radioprotective potential of VitD and melatonin is another exciting area of exploration. Combining these agents with radiotherapy may improve its effectiveness while mitigating side effects. However, further research is crucial to determine the optimal and safe dosage. Considering the prevalence of VitD and melatonin deficiencies in society, supplementation becomes particularly relevant since their lower levels can worsen the side effects of cancer treatments like radiotherapy and chemotherapy. Additionally, the sleep-promoting effects of melatonin may indirectly benefit cancer patients through its impact on the immune system. Large-scale controlled trials are needed to definitively establish the efficacy of combining VitD and melatonin in improving cancer patients´ lives. This approach shows considerable promise owing to its affordability, lack of toxicity, and dependence, in addition to the potential synergy between these readily available agents.
Fil: Reiter, Russel. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos
Fil: De Almeida Chuffa, Luiz. Universidade Estadual Paulista Julio de Mesquita Filho; Brasil
Fil: Simão, Vinícius. Universidade Estadual Paulista Julio de Mesquita Filho; Brasil
Fil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Católica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; Argentina. Universidad de Santiago de Compostela; España
Fil: de Las Heras, Natalia. Universidad Complutense de Madrid. Facultad de Medicina. Departamento de Fisiología; España
Fil: Spandidos, Demetrios. University Of Crete. School Of Medicine; Grecia
Fil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Farmacología; Argentina - Materia
-
CANCER
MELATONIN
VITAMIN D
SYNERGISM - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/265154
Ver los metadatos del registro completo
id |
CONICETDig_e484c06b00933bcab0d02904ef7cad0e |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/265154 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapyReiter, RusselDe Almeida Chuffa, LuizSimão, ViníciusMartín Giménez, Virna Margaritade Las Heras, NataliaSpandidos, DemetriosManucha, Walter Ariel FernandoCANCERMELATONINVITAMIN DSYNERGISMhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Melatonin and vitamin D (VitD) hold significant promise in cancer prevention and treatment due to their shared anti-inflammatory, immune-boosting, and anti-cancer properties. Deficiencies in both agents can arise from modern lifestyles, with low sunlight exposure impacting VitD and excessive artificial light at night suppressing melatonin. Several studies highlight the potential of combining VitD and melatonin supplementation against various cancer types. Research on lip, oral, and pharynx cancers suggests this combination could address antioxidant imbalances linked to the disease. Similarly, promising results from breast, head and neck, brain, and osteosarcoma studies indicate potential for tumor growth inhibition and improved survival and quality of life. Beyond tumor control, this combination has shown significant benefits in lung cancer patients by improving survival, alleviating respiratory symptoms, and enhancing patient’s quality of life. The radioprotective potential of VitD and melatonin is another exciting area of exploration. Combining these agents with radiotherapy may improve its effectiveness while mitigating side effects. However, further research is crucial to determine the optimal and safe dosage. Considering the prevalence of VitD and melatonin deficiencies in society, supplementation becomes particularly relevant since their lower levels can worsen the side effects of cancer treatments like radiotherapy and chemotherapy. Additionally, the sleep-promoting effects of melatonin may indirectly benefit cancer patients through its impact on the immune system. Large-scale controlled trials are needed to definitively establish the efficacy of combining VitD and melatonin in improving cancer patients´ lives. This approach shows considerable promise owing to its affordability, lack of toxicity, and dependence, in addition to the potential synergy between these readily available agents.Fil: Reiter, Russel. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados UnidosFil: De Almeida Chuffa, Luiz. Universidade Estadual Paulista Julio de Mesquita Filho; BrasilFil: Simão, Vinícius. Universidade Estadual Paulista Julio de Mesquita Filho; BrasilFil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Católica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; Argentina. Universidad de Santiago de Compostela; EspañaFil: de Las Heras, Natalia. Universidad Complutense de Madrid. Facultad de Medicina. Departamento de Fisiología; EspañaFil: Spandidos, Demetrios. University Of Crete. School Of Medicine; GreciaFil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Farmacología; ArgentinaSpandidos Publications2024-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/265154Reiter, Russel; De Almeida Chuffa, Luiz; Simão, Vinícius; Martín Giménez, Virna Margarita; de Las Heras, Natalia; et al.; Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy; Spandidos Publications; International Journal of Oncology; 65; 6; 10-2024; 1-221019-6439CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.spandidos-publications.com/10.3892/ijo.2024.5702info:eu-repo/semantics/altIdentifier/doi/10.3892/ijo.2024.5702info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:43:17Zoai:ri.conicet.gov.ar:11336/265154instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:43:17.84CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy |
title |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy |
spellingShingle |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy Reiter, Russel CANCER MELATONIN VITAMIN D SYNERGISM |
title_short |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy |
title_full |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy |
title_fullStr |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy |
title_full_unstemmed |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy |
title_sort |
Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy |
dc.creator.none.fl_str_mv |
Reiter, Russel De Almeida Chuffa, Luiz Simão, Vinícius Martín Giménez, Virna Margarita de Las Heras, Natalia Spandidos, Demetrios Manucha, Walter Ariel Fernando |
author |
Reiter, Russel |
author_facet |
Reiter, Russel De Almeida Chuffa, Luiz Simão, Vinícius Martín Giménez, Virna Margarita de Las Heras, Natalia Spandidos, Demetrios Manucha, Walter Ariel Fernando |
author_role |
author |
author2 |
De Almeida Chuffa, Luiz Simão, Vinícius Martín Giménez, Virna Margarita de Las Heras, Natalia Spandidos, Demetrios Manucha, Walter Ariel Fernando |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
CANCER MELATONIN VITAMIN D SYNERGISM |
topic |
CANCER MELATONIN VITAMIN D SYNERGISM |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Melatonin and vitamin D (VitD) hold significant promise in cancer prevention and treatment due to their shared anti-inflammatory, immune-boosting, and anti-cancer properties. Deficiencies in both agents can arise from modern lifestyles, with low sunlight exposure impacting VitD and excessive artificial light at night suppressing melatonin. Several studies highlight the potential of combining VitD and melatonin supplementation against various cancer types. Research on lip, oral, and pharynx cancers suggests this combination could address antioxidant imbalances linked to the disease. Similarly, promising results from breast, head and neck, brain, and osteosarcoma studies indicate potential for tumor growth inhibition and improved survival and quality of life. Beyond tumor control, this combination has shown significant benefits in lung cancer patients by improving survival, alleviating respiratory symptoms, and enhancing patient’s quality of life. The radioprotective potential of VitD and melatonin is another exciting area of exploration. Combining these agents with radiotherapy may improve its effectiveness while mitigating side effects. However, further research is crucial to determine the optimal and safe dosage. Considering the prevalence of VitD and melatonin deficiencies in society, supplementation becomes particularly relevant since their lower levels can worsen the side effects of cancer treatments like radiotherapy and chemotherapy. Additionally, the sleep-promoting effects of melatonin may indirectly benefit cancer patients through its impact on the immune system. Large-scale controlled trials are needed to definitively establish the efficacy of combining VitD and melatonin in improving cancer patients´ lives. This approach shows considerable promise owing to its affordability, lack of toxicity, and dependence, in addition to the potential synergy between these readily available agents. Fil: Reiter, Russel. University Of Texas At San Antonio. University Of Texas Health Science Center At San Antonio (ut Health San Antonio); Estados Unidos Fil: De Almeida Chuffa, Luiz. Universidade Estadual Paulista Julio de Mesquita Filho; Brasil Fil: Simão, Vinícius. Universidade Estadual Paulista Julio de Mesquita Filho; Brasil Fil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Católica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; Argentina. Universidad de Santiago de Compostela; España Fil: de Las Heras, Natalia. Universidad Complutense de Madrid. Facultad de Medicina. Departamento de Fisiología; España Fil: Spandidos, Demetrios. University Of Crete. School Of Medicine; Grecia Fil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Farmacología; Argentina |
description |
Melatonin and vitamin D (VitD) hold significant promise in cancer prevention and treatment due to their shared anti-inflammatory, immune-boosting, and anti-cancer properties. Deficiencies in both agents can arise from modern lifestyles, with low sunlight exposure impacting VitD and excessive artificial light at night suppressing melatonin. Several studies highlight the potential of combining VitD and melatonin supplementation against various cancer types. Research on lip, oral, and pharynx cancers suggests this combination could address antioxidant imbalances linked to the disease. Similarly, promising results from breast, head and neck, brain, and osteosarcoma studies indicate potential for tumor growth inhibition and improved survival and quality of life. Beyond tumor control, this combination has shown significant benefits in lung cancer patients by improving survival, alleviating respiratory symptoms, and enhancing patient’s quality of life. The radioprotective potential of VitD and melatonin is another exciting area of exploration. Combining these agents with radiotherapy may improve its effectiveness while mitigating side effects. However, further research is crucial to determine the optimal and safe dosage. Considering the prevalence of VitD and melatonin deficiencies in society, supplementation becomes particularly relevant since their lower levels can worsen the side effects of cancer treatments like radiotherapy and chemotherapy. Additionally, the sleep-promoting effects of melatonin may indirectly benefit cancer patients through its impact on the immune system. Large-scale controlled trials are needed to definitively establish the efficacy of combining VitD and melatonin in improving cancer patients´ lives. This approach shows considerable promise owing to its affordability, lack of toxicity, and dependence, in addition to the potential synergy between these readily available agents. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/265154 Reiter, Russel; De Almeida Chuffa, Luiz; Simão, Vinícius; Martín Giménez, Virna Margarita; de Las Heras, Natalia; et al.; Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy; Spandidos Publications; International Journal of Oncology; 65; 6; 10-2024; 1-22 1019-6439 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/265154 |
identifier_str_mv |
Reiter, Russel; De Almeida Chuffa, Luiz; Simão, Vinícius; Martín Giménez, Virna Margarita; de Las Heras, Natalia; et al.; Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy; Spandidos Publications; International Journal of Oncology; 65; 6; 10-2024; 1-22 1019-6439 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.spandidos-publications.com/10.3892/ijo.2024.5702 info:eu-repo/semantics/altIdentifier/doi/10.3892/ijo.2024.5702 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Spandidos Publications |
publisher.none.fl_str_mv |
Spandidos Publications |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613362728566784 |
score |
13.069144 |